Friday, December 10, 2021
11:15 AM EST – Oncolytics Biotech Inc. : Announced a positive interim safety update from the investigator-sponsored, phase 2 IRENE trial in a poster presentation at the 2021 San Antonio Breast Cancer Symposium. The IRENE trial is designed to evaluate the safety and efficacy of pelareorep in combination with Incyte’s anti-PD-1 checkpoint inhibitor retifanlimab for second- or third-line treatment of patients with metastatic triple-negative breast cancer. Oncolytics Biotech Inc. (T.ONC) shares were unchanged at 2.08.
Stocks in Play: Oncolytics Biotech Inc., Fri, 10 Dec 2021 11:27:06 EST